Knowledge graph · Cancer
Indolent Non-Hodgkin Lymphoma
hematologic malignancy
- Identifier
- CI-CAN-00005564
- Entity page
- /cancer/indolent-non-hodgkin-lymphoma ↗
- Edges
- 944
- Neighbours
- 22 drugs10 trials
- Drawn
- 32 of 32 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Indolent Non-Hodgkin Lymphoma approved for …APPROVED_FORderived31 of 31show fewer | ||||||||
| ← approved for | Vorasidenibsmall molecule EMA (EU) · approved · 2025-09-17 · Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an… | — | approved | Grade 2 Follicular Lymphoma | 1 | Regulatory | ema | graph → |
| approved for | ||||||||